Open-house rebate agreement for Dornase alfa

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Aug 03, 2027 · 340 days left·Open·Supplies·Framework

Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dornase alfa (Desoxyribonuclease), ATC R05CB13

46/100

Opportunity Score

Needs reviewMedium complexity

SuppliesFrameworkOpen

Why this score?

Opportunity

46 / 100

Complexity

58 / 100

Risk factors

The notice explicitly says the contract documents must be submitted via the DTVP communication area and not via the off...

Contract conclusion is only possible until 03.08.2027, and monthly start dates depend on receipt of complete documents...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Overview

Moderate opportunity

Key Facts

Framework procurement
Supplies contract
1 lot
Duration until Sep 2027
Non-exclusive open-house rebate agreement for Dornase alfa (Desoxyribonuclease), ATC R05CB13.
Supply of pharmaceutical products under a predefined rebate contract.

Show full summary

This is an open-house pharmaceutical supply arrangement by AOK Bayern for Dornase alfa (Desoxyribonuclease), ATC R05CB13, not a competitive award procedure in the usual sense. The model is non-exclusive and open to all pharmaceutical companies that meet the stated suitability requirement. No contract value is provided. Submission is possible electronically with a qualified electronic signature via DTVP or in paper form in duplicate originals. The deadline for contract conclusion is 03.08.2027, with monthly entry dates depending on when complete documents are received.

Risks

The notice explicitly says the contract documents must be submitted via the DTVP communication area and not via the off...

Contract conclusion is only possible until 03.08.2027, and monthly start dates depend on receipt of complete documents...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Eligibility

Only pharmaceutical companies are eligible as potential contract partners.

Administrative

A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
The signed contract and the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Buyer

Name

AOK Bayern - Die Gesundheitskasse

Location

München, DEU

[email protected]

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Dornase alfa

Open-house non-exclusive rebate agreement for the medicinal product Dornase alfa (Desoxyribonuclease), ATC R05CB13. The lot is for pharmaceutical products and is described as a supply arrangement. The notice states that the contract conditions are predefined and not individually negotiable. Source: structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Sep 2025 - Sep 2027

Procurement Details

Publication date: 13 Aug 2025
Languages: German

Reference metadata

Legal basis: 32014L0024

Reference IDs

Tender ID: 533448-2025

Documents (2)

Procurement document 1 Submission portal 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3